Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


OTCPK:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Watch Dopesick on Disney Plus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(22)
•••
Post by Forestviewon Jan 03, 2023 11:19am
785 Views
Post# 35200727

Watch Dopesick on Disney Plus

Watch Dopesick on Disney PlusHey all, happy new year.  Like many of you, I took the time to binge watch some TV over the holidays.  One show I recommend all of you to watch is Dopesick, based on Purdue Pharma's development of OxyContin, and how its highly addictive nature (which Purdue grossly downplayed) decimated the lives of tens of thousands of people.  If anyone wonders what ATE is doing, and the potential impact it may have on the world, this series will reinforce its importance.  

I hope ATE continues to make progress in 2023, there is a real, tangible market for Otena, and others.  

Good luck longs.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities